弘星相和

HiDiamond Biotechnology (弘星相和) is a clinical-stage biopharmaceutical company founded in 2021 by Dr. Shao Ying, a former senior official at China's Center for Drug Evaluation (CDE) and executive at Fosun Pharma. The company operates under a "Hub and Spoke" model, focusing on the early-stage proof-of-concept (POC) validation of innovative global targets in oncology, autoimmune diseases, and metabolic disorders. Its lead candidate, HiD21 (QTX125), is a highly selective HDAC6 inhibitor currently in Phase 1 clinical trials for advanced solid and hematological tumors. HiDiamond leverages advanced AI and bio-organoid platforms to accelerate drug discovery and development, integrating global innovation with China's efficient R&D ecosystem. The company has secured significant funding from prominent investors like Northern Light Venture Capital and CDH Investments to advance its diverse pipeline of small molecules and biologics. With a strategic focus on epigenetic targets, HiDiamond aims to provide transformative treatments for patients with high unmet medical needs worldwide.